Given our previous results regarding ATRA response and previous studies highlighting the pro‐differentiation effects on AML of inhibiting CYP26, a key player in retinol metabolism,8 we next combined ATRA and the CYP26 inhibitor talarozole in control and HRH1‐KD HL60 cells. The gene discussed is HRH1; the disease is acute myeloid leukemia.